London, Royal College of Physician (Stand # 5)14 September 2011
BUBENDORF, Switzerland (September 15, 2011) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is exhibiting at the Biotech Outsourcing Strategies (BOS cmc), on September 20th in London, at the Royal College of Physician (Stand # 5).
During the BOS conference program (non-clinical track), Mrs. Pam Cumberbirch, CARBOGEN AMCIS’ marketing specialist, will give a presentation entitled: “CARBOGEN AMCIS – enabling your innovation” at 12.20-12.30 am.
If you would like to arrange to speak with one of our representatives at the meeting please contact:
Mrs. Pam Cumberbirch email@example.com Mob: (+44) 77 03 12 81 7
CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.
Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.
Bio2Business Ltd (www.bio2bevents.com) is a life science consultancy based in London. Formed in August 2004 Bio2Business facilitates partnering in the UK biotech sector through targeted business development activities. Bio2Business Event Management division is dedicated to building the Biotech Outsourcing Strategies (BOS) series of events. BOS events are primarily business 2 business partnering events to bring together biotech drug development executives and high quality service providers in small molecule and biopharmaceutical drug development.